GSK still trades about 17 per cent lower than when the worries about Zantac emerged in August last year. GSK said it will contest the cases vigorously but with court dates set into 2024, the hangover is likely to persist.
Despite good faith efforts, the closing conditions provided for in the share purchase agreement had not been fully satisfied as of December 31, 2023, the long stop date, and on January 1, 2024, we exercised our right to terminate the share purchase agreement based on the terms of the ...